Galmed Pharmaceuticals Ltd. reported a net loss of $2.4 million for the six months ending June 30, 2024, an improvement from a $3.4 million loss during the same period in 2023, with cash and cash equivalents at $1.8 million as of June 30, 2024. This filing relates to their quarterly financial results and is not significant for equity investors.